 On the BioSecure Act, which will halt federal contracts with biotech companies that are beholden to adversaries and endanger Americans' health care data, will rein in the de minimis privilege for any good subject to Section 301 trade enforcement tariffs. And that will help stymie China's attempts to exploit American trade.